DK1107795T3 - Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis - Google Patents

Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis

Info

Publication number
DK1107795T3
DK1107795T3 DK99952903T DK99952903T DK1107795T3 DK 1107795 T3 DK1107795 T3 DK 1107795T3 DK 99952903 T DK99952903 T DK 99952903T DK 99952903 T DK99952903 T DK 99952903T DK 1107795 T3 DK1107795 T3 DK 1107795T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
cancer
thiomolybdate
carbohydrate
Prior art date
Application number
DK99952903T
Other languages
English (en)
Inventor
George J Brewer
Sofia D Merajver
Nathan Ockwig
Dimitri Coucouvanis
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of DK1107795T3 publication Critical patent/DK1107795T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99952903T 1998-09-04 1999-09-03 Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis DK1107795T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9910398P 1998-09-04 1998-09-04
US10175998P 1998-09-25 1998-09-25
PCT/US1999/020374 WO2000013712A2 (en) 1998-09-04 1999-09-03 Methods and compositions for the prevention or treatment of cancer

Publications (1)

Publication Number Publication Date
DK1107795T3 true DK1107795T3 (da) 2003-03-24

Family

ID=26795562

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99952903T DK1107795T3 (da) 1998-09-04 1999-09-03 Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis

Country Status (14)

Country Link
EP (1) EP1107795B1 (da)
JP (1) JP2002524426A (da)
KR (1) KR100702279B1 (da)
CN (1) CN100548383C (da)
AT (1) ATE228375T1 (da)
AU (1) AU773848B2 (da)
CA (1) CA2341752A1 (da)
DE (1) DE69904203T2 (da)
DK (1) DK1107795T3 (da)
ES (1) ES2188261T3 (da)
IL (1) IL141550A0 (da)
NZ (1) NZ510038A (da)
PT (1) PT1107795E (da)
WO (1) WO2000013712A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
EP1531827A4 (en) * 2002-05-24 2009-07-08 Univ Michigan COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES
US20070292533A1 (en) * 2002-05-24 2007-12-20 Regents Of The University Of Michigan Copper lowering treatment of autoimmune diseases
GEP20074270B (en) 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
JP2007516234A (ja) * 2003-05-27 2007-06-21 アテニュオン，リミティド ライアビリティー カンパニー チオタングステン酸（塩）アナログ及びその使用
AU2005217623A1 (en) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
CA2675230A1 (en) * 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
WO2009009622A2 (en) * 2007-07-09 2009-01-15 Pipex Pharmaceuticals, Inc. Pharmaceutical compositions, including attm, and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
KR100972355B1 (ko) * 2008-05-08 2010-07-26 고려전자주식회사 순간식 가스보일러의 온수공급라인용 써모밸브조립체
GB201005394D0 (en) * 2010-03-30 2010-05-12 Magnus Intellectual Property Ltd Therapy
US10478455B2 (en) 2010-03-30 2019-11-19 Ucl Business Ltd Therapeutic use of tetrathiomolybdate
US20160220500A1 (en) * 2014-11-14 2016-08-04 Kent State University Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer
CN108634322A (zh) * 2018-05-16 2018-10-12 刘华 一种预防和调理癌症的方法
SG11202011680YA (en) * 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders

Also Published As

Publication number Publication date
CN1457261A (zh) 2003-11-19
DE69904203D1 (de) 2003-01-09
NZ510038A (en) 2003-10-31
AU773848B2 (en) 2004-06-10
JP2002524426A (ja) 2002-08-06
WO2000013712A3 (en) 2000-09-28
AU6496099A (en) 2000-03-27
EP1107795B1 (en) 2002-11-27
DE69904203T2 (de) 2003-08-14
CA2341752A1 (en) 2000-03-16
CN100548383C (zh) 2009-10-14
ATE228375T1 (de) 2002-12-15
IL141550A0 (en) 2002-03-10
WO2000013712A2 (en) 2000-03-16
PT1107795E (pt) 2003-04-30
ES2188261T3 (es) 2003-06-16
EP1107795A2 (en) 2001-06-20
KR100702279B1 (ko) 2007-04-02
KR20010082190A (ko) 2001-08-29

Similar Documents

Publication Publication Date Title
DK1107795T3 (da) Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
SI2269656T1 (sl) Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
IL158088A (en) Use of an antibody linked to ailim for the preparation of a pharmacological preparation for suppressing or preventing inflammatory bowel disease
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
IL146125A0 (en) Novel quinones as disease therapies
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
EP1790728A3 (en) Imaging, diagnosis and treatment of disease
MXPA03008423A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2003035688A3 (en) Targeted thrombosis by tissue factor polypeptides
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
TR200200278T2 (tr) Kalsilitik bileşimler
EP1234585A3 (en) Methods and compositions for the prevention or treatment of cancer
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
DK1253935T3 (da) Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
NZ514691A (en) Method to type prion proteins